Rosuvastatin/telmisartan - Yuhan

Drug Profile

Rosuvastatin/telmisartan - Yuhan

Alternative Names: Duo Wellness; Duowell; Telmisartan/rosuvastatin; YH-16410; YMC 017

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Yuhan
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 28 Oct 2016 Chemical structure information added
  • 01 Jun 2014 Yuhan completes a phase III trial in Hyperlipidaemia & Hypertension in South Korea (NCT01914432)
  • 30 Nov 2013 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top